Oncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a note issued to investors on Saturday. The firm set a “hold” rating on the stock.

ONCT has been the subject of a number of other reports. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. HC Wainwright dropped their price target on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Northland Securities reissued a “market perform” rating and set a $2.00 target price on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, Northland Capmk lowered Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.00.

Oncternal Therapeutics Price Performance

Shares of ONCT stock opened at $1.49 on Friday. The business has a fifty day moving average of $2.50 and a 200 day moving average of $5.97. Oncternal Therapeutics has a 1 year low of $1.05 and a 1 year high of $13.14. The firm has a market capitalization of $4.41 million, a price-to-earnings ratio of -0.12 and a beta of 1.36.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, topping the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.24 million. During the same quarter in the prior year, the company earned ($3.00) EPS. As a group, equities research analysts expect that Oncternal Therapeutics will post -12.43 earnings per share for the current year.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.